S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akorn, Inc. stock logo
AKRX
Akorn
$0.19
$0.09
$5.46
$3.60M0.959.60 million shs1.19 million shs
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
$2.06
$1.26
$4.26
$8.11M0.98162,968 shs2,579 shs
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.18
-27.2%
$1.82
$1.10
$9.38
$740K12.09 million shs2.22 million shs
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$0.22
$0.22
$0.08
$0.34
$56.90M2.65,474 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akorn, Inc. stock logo
AKRX
Akorn
0.00%0.00%0.00%0.00%0.00%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-27.16%-28.48%-29.34%-32.95%-80.33%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akorn, Inc. stock logo
AKRX
Akorn
$682.43M0.00N/A0.19$1.86 per share0.00
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A$2.48 per shareN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.97M0.28N/AN/A$32.12 per share0.04
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$7.38M7.71N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akorn, Inc. stock logo
AKRX
Akorn
-$226.77M-$0.34N/AN/AN/A-55.64%8.53%1.31%N/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
-$8.64MN/A0.00N/AN/AN/A-72.60%-55.68%N/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-$5.93MN/A0.00N/AN/AN/AN/A7/29/2024 (Estimated)
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
-$18.79M-$0.08N/AN/A-254.66%-346.72%-94.54%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akorn, Inc. stock logo
AKRX
Akorn
0.09
0.50
0.32
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/A
3.37
3.37
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.02
1.47
1.41
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.64
1.35
0.90

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akorn, Inc. stock logo
AKRX
Akorn
64.03%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
7.49%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
5.02%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.02%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akorn, Inc. stock logo
AKRX
Akorn
2,227133.15 millionN/AOptionable
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
54.48 millionN/AOptionable
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
78460,000439,000Not Optionable
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
29258.62 millionN/ANot Optionable

SXTC, TRLPF, REXN, and AKRX Headlines

SourceHeadline
Takeda Pharmaceutical Co. Ltd. ADRTakeda Pharmaceutical Co. Ltd. ADR
wsj.com - February 8 at 10:03 AM
Other OTC Pharmaceuticals - LithuaniaOther OTC Pharmaceuticals - Lithuania
statista.com - September 17 at 1:59 AM
2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit
seekingalpha.com - January 1 at 9:14 AM
Acerus Reports Second Quarter 2022 Financial ResultsAcerus Reports Second Quarter 2022 Financial Results
financialpost.com - August 9 at 7:47 AM
Acerus Reports Fourth Quarter and Full Year 2021 Financial ResultsAcerus Reports Fourth Quarter and Full Year 2021 Financial Results
financialpost.com - March 15 at 7:47 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akorn logo

Akorn

NASDAQ:AKRX
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Rexahn Pharmaceuticals logo

Rexahn Pharmaceuticals

NASDAQ:REXN
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
China SXT Pharmaceuticals logo

China SXT Pharmaceuticals

NASDAQ:SXTC
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
Acerus Pharmaceuticals logo

Acerus Pharmaceuticals

OTCMKTS:TRLPF
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.